S&P 500 Technology Sector SEC Filings — June 08, 2026

08-06-2026

Diana Shipping Inc., the largest shareholder of Genco Shipping & Trading Ltd (GNK), filed an amendment to its Schedule 13D and Schedule TO, narrowing its proxy contest slate to two nominees—Jens Ismar and Paul Cornell—for election to Genco's Board at the June 18, 2026 Annual Meeting. Diana is also conducting a cash tender offer to purchase all outstanding Genco shares at $24.80 per share, and warns that if its nominees are not elected, it may reassess the offer. The filing reflects ongoing activist pressure to replace two incumbent directors, Arthur L. Regan and Basil G. Mavroleon, and highlights ISS support for removing Genco's poison pill.

• · The tender offer expires at 5:00 p.m. New York City time on June 26, 2026, unless extended.
• · Diana's nominees have no financial relationship with Diana; they were chosen for drybulk industry experience and independence.
• · Jens Ismar previously served as CEO of Western Bulk for 11 years, growing the fleet from 60 to 150 vessels and leading its Oslo Stock Exchange listing.
• · Paul Cornell co-founded Quintana Maritime in 2005, grew it into a major drybulk carrier, and sold it for significant investor returns; he also co-founded a second Quintana entity sold to Golden Ocean.
• · ISS recommended voting against Genco's poison pill, which Diana cites as validation of its concerns.
• · Shareholders who already voted the GOLD card for Ismar and Cornell need not take further action; those who voted the WHITE card can change their vote by returning the GOLD card.
• · The filing is Amendment No. 10 to the Schedule TO originally filed on May 4, 2026.

08-06-2026

On June 4, 2026, Jordan Krugman notified the Invesco CurrencyShares Canadian Dollar Trust of his resignation from all positions at the Sponsor, Invesco Specialized Products, LLC, and its affiliates, including his role on the Board of Managers, effective August 3, 2026. The Sponsor is currently considering a replacement. No financial impact or performance data is provided in this filing.

• · Resignation effective date: August 3, 2026.
• · Filing date: June 8, 2026; event date: June 4, 2026.
• · Sponsor is actively considering a replacement for Mr. Krugman.

08-06-2026

Intuitive Machines, Inc. held its Annual Meeting of Stockholders on June 4, 2026, where shareholders elected two Class III director nominees (Dr. Kamal Ghaffarian and Stephen Altemus) to terms expiring in 2029, and ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026. Both proposals passed with strong shareholder support, though the director elections saw notable votes against and broker non-votes.

• · The Annual Meeting was held on June 4, 2026, and the 8-K was filed on June 8, 2026.
• · Dr. Kamal Ghaffarian received 195,999,331 votes for and 22,328,731 votes against, with 28,971,750 broker non-votes.
• · Stephen Altemus received 207,762,049 votes for and 10,566,013 votes against, with 28,971,750 broker non-votes.
• · Grant Thornton LLP was ratified with 246,639,121 votes for, 280,218 against, and 380,473 abstentions.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

08-06-2026

AvalonBay Communities, Inc. announced the executive leadership team for the combined company that will be formed upon closing of its merger with Equity Residential, expected in the second half of 2026. The team includes leaders from both organizations, such as Michael Manelis (COO, from Equity Residential) and Scott Fenster (General Counsel, from Equity Residential), while Kevin O'Shea (CFO) and others will continue from AvalonBay. The announcement marks a key integration milestone, but the companies will remain separate until closing, and organizational structures for certain groups are still being determined.

• · The combined company will oversee more than 180,000 apartment homes.
• · Closing is expected in the second half of 2026; until then, both companies operate separately under current leadership.
• · Ted Schulman will serve as EVP of Legal Affairs through integration, then transition to a senior advisor role.
• · Organizational structure and reporting relationships for certain groups are still being determined.
• · Town halls will be held in Arlington and Chicago with livestream access for all associates.

08-06-2026

AParadise II Acquisition Corp., a blank check company incorporated in the British Virgin Islands, filed an S-1 registration statement on June 8, 2026, for an initial public offering of 13,500,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. The offering aims to raise $135,000,000, with an additional over-allotment option of up to 2,025,000 units. The company has not yet selected any business combination target and has not initiated substantive discussions with any target.

• · The company is a blank check company (SIC 6770) formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
• · The underwriters have a 45-day option to purchase up to an additional 2,025,000 units to cover over-allotments.
• · The sponsor and CCM have committed to purchase an aggregate of 485,000 private placement units (or 525,500 if over-allotment is exercised in full) at $10.00 per unit.
• · Non-voting sponsor investors have expressed interest to indirectly purchase an aggregate of [•] private placement units through the purchase of non-voting interests in the sponsor.
• · Public shareholders have redemption rights upon completion of the initial business combination, with a limitation that a shareholder acting in concert or as a group cannot redeem more than 15% of the shares sold in the offering without prior consent.
• · The company has not selected any business combination target and has not initiated any substantive discussions with any target.
• · The company is an emerging growth company and a smaller reporting company.

08-06-2026

Madison Square Garden Entertainment Corp. (MSGE) announced on June 8, 2026, that it entered a non-binding memorandum of understanding with the Master Developer (Penn Transformation Partners) for the redevelopment of New York Penn Station. The MOU acknowledges that The Madison Square Garden Arena must remain fully operational at all times and contemplates the transfer of the Infosys Theater at MSG to the Master Developer, subject to further definitive agreements. There are no assurances that the redevelopment or the theater transfer will be completed.

• · The MOU is non-binding and subject to execution of Developer Agreements between Amtrak and the Master Developer.
• · The transfer of Infosys Theater at MSG is contemplated but requires further negotiation and definitive documentation.
• · The filing is a Regulation FD Disclosure (Item 7.01) and does not contain financial results or quantitative data.

08-06-2026

United Community Banks Inc (UCB) is acquiring Peach State in a merger where Peach State shareholders can elect to receive either $31.75 in cash or 0.8978 shares of UCB common stock per share, subject to proration so that 50% of Peach State shares will be converted into cash and 50% into stock. The merger is subject to regulatory approvals and other closing conditions, and there are significant risks including potential failure to qualify as a tax-free reorganization, stock price fluctuations affecting consideration value, and integration challenges that could delay or reduce anticipated benefits.

• · Exchange ratio for stock consideration is 0.8978 shares of UCB common stock per Peach State share.
• · Peach State common stock is not listed on any exchange and has no established market.
• · Merger is conditioned on receipt of tax opinions that it qualifies as a 'reorganization' under Section 368(a) of the Internal Revenue Code.
• · Regulatory approvals required from the Federal Reserve Board, the SCBFI, and other state/federal authorities.
• · Integration risks include potential loss of key employees, customer attrition, and diversion of management attention.
• · No adjustment to merger consideration for changes in UCB stock price prior to completion.

08-06-2026

Shenandoah Telecommunications Company (SHEN) announced the resignation of Board member James F. DiMola effective June 8, 2026, and the immediate election of Matthew D. Rinklin as his replacement. DiMola's departure is not due to any disagreement with the company. Rinklin, a Managing Director at GCM Grosvenor L.P., was appointed by the Board upon recommendation from the Investor (LIF Vista, LLC) under the Investor Rights Agreement, and will serve as a Class 3 director until the 2027 annual meeting.

• · Mr. Rinklin has served as Managing Director at GCM Grosvenor L.P. since June 2018.
• · Mr. Rinklin will serve on the Company’s Nominating and Corporate Governance Committee.
• · Mr. Rinklin will receive standard director compensation as described in the Company’s Definitive Proxy Statement filed March 9, 2026.
• · The Investor Rights Agreement was originally disclosed in the Company’s Form 8-K filed April 1, 2024.

08-06-2026

AIM ImmunoTech Inc. filed an S-1 registration statement for the resale of up to 31,287,933 shares of common stock by selling stockholders, which includes shares underlying Class H, Class I, and placement agent warrants. The company will not receive any proceeds from the stock sales, but could receive up to approximately $14.5 million if all warrants are exercised for cash. While the company highlights progress in its Phase 2 DURIPANC study for pancreatic cancer and a planned Phase 3 trial with Thermo Fisher Scientific, it also notes that Ampligen has not been approved by the FDA in the U.S. and faces significant risks, including a highly speculative investment profile.

• · Ampligen is approved for commercial sale in Argentina for severe Chronic Fatigue Syndrome, but not FDA-approved in the U.S.
• · The company has orphan drug designations for pancreatic cancer in the U.S. and EU.
• · The DURIPANC study is an investigator-initiated, open-label, single-center study at Erasmus MC.
• · AIM announced an agreement with Thermo Fisher Scientific in March 2026 to design a Phase 3 trial for Ampligen in late-stage pancreatic cancer.
• · The company has conducted animal studies showing Ampligen's antiviral activity against SARS-CoV-2, Ebola, and other viruses.
• · The WHO declared the Ebola outbreak involving the Bundibugyo strain a Public Health Emergency of International Concern.
• · As of May 29, 2026, there were 24,328,623 shares of common stock outstanding.
• · Outstanding options and warrants (excluding those in the offering) could result in additional shares: 1,173 options at $1,669.99, 23,860 options at $152.55, 3,600 consultant options at $46.00, 2,593,189 Class E/F warrants at $1.439, 100,000 participating warrants at $4.40, and 3,374,000 Class G warrants at $1.00.